reported 25% growth in third-quarter earnings, topping analysts' expectations by a penny due to overall strong sales of pacemakers and defibrillators.
The company earned $122.8 million, or 40 cents a share, compared with $98.2 million, or 32 cents a share, in the same quarter last year. Last year's earnings include a charge of $7.6 million, or 2 cents a share. A
First Call/Thomson Financial
poll of 28 analysts gave an estimate of 39 cents a share.
Overall sales for the third quarter rose to $600.8 million from $569 million last year.